Novavax reported $734.58M in Sales Revenues for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Sales Change
Adma Biologics ADMA:US USD 41.09M 7.18M
Agenus AGEN:US USD 22.77M 1.85M
Astrazeneca AZN:US USD 10.98B 211M
AstraZeneca AZN:LN USD 10.98B 211M
Biocryst Pharmaceuticals BCRX:US USD 75.83M 10.3M
Dynavax Technologies DVAX:US USD 167.74M 88.73M
Genocea Biosciences GNCA:US USD 270K 270K
Geron GERN:US USD 297K 224K
GlaxoSmithKline GSK:LN GBP 782.9B 90B
Mannkind MNKD:US USD 32.82M 13.93M
Merk MRK:US USD 14.96B 366M
Moderna Inc MRNA:US USD 3.36B 1.38B
Novartis NVS:US USD 12.84B 243M
Novavax NVAX:US USD 734.58M 548.65M
Peregrine Pharmaceuticals PPHM:US USD 36.69M 5.47M
Pfizer PFE:US USD 22.64B 5.1B
Sarepta Therapeutics SRPT:US USD 230.27M 3.22M
Tg Therapeutics TGTX:US USD 94K 500K